Navigation Links
Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
Date:1/12/2009

30 total patients will be treated.

New Alliance for Use of Quadra-Fuse, Multi-pronged Injection Needles

Jennerex also announced today an alliance with Rex Medical, a manufacturer of advanced multi-pronged needles, for the targeted intratumoral administration of JX-594. Jennerex shall exclusively use Rex Medical Quadra-Fuse needles ("QF Needles") for intratumoral injections of JX-594 in clinical development, and Rex Medical shall work collaboratively with Jennerex to effectively apply this technology to JX-594 clinical development.

"We are excited to be collaborating with Rex Medical, the market leader in this field, for application of Quadra-Fuse needle technology with JX-594. This is the first needle designed for optimizing therapeutic delivery of fluids/agents into target tissue zones. This innovative multi-pronged design allows us to precisely target distribution of JX-594 for optimal therapeutic effect. The result is an innovative and potentially landmark combination of a highly targeted biotherapeutic agent with a sophisticated medical device for targeted delivery," stated Dr. Kirn.

About JX-594

JX-594 is a cancer biotherapeutic product, currently in Phase 2 trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types on three Phase 1 trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeated. Normal cells are not affected by JX-594 resulting in safety and tolerability. The poxvirus strain backbone of JX-594 has
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
2. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
3. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
4. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
5. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
6. New Data Shows Veramyst Effectively Treats Symptoms of Perennial Allergic Rhinitis
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
10. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  Lakeland Industries, Inc. (NASDAQ: ... for industry, healthcare and to first responders on the ... results for the fiscal 2013 fourth quarter and year ... at stock market close and will conduct a conference ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) ...
(Date:5/17/2013)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today announced ... Global Healthcare Conference in New York . ... at 11 a.m. Eastern Time. To listen to the live ... Investor Relations section of the Company,s Web site at ... after the event. About Orexigen® Therapeutics Orexigen ...
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
Breaking Medicine Technology:Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
... ACCESS PHARMACEUTICALS, INC.,(OTC Bulletin Board: ACCP) announced ... performed by Access collaborators at two,prominent institutes ... the joint,symposium of the American Association for ... European Organization for Research and Treatment,of Cancer ...
... Cells has Potential to Yield High ... and Therapeutic Products, ST. LOUIS and RICHMOND, Calif., Oct. ... Inc.,(Nasdaq: SGMO ) announced today the publication of data ... human stem,cells. This work represents a significant advance in the ...
Cached Medicine Technology:Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 3Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 2Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 3Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 4Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells 5
(Date:5/20/2013)... comprised over 24,000 Finnish subjects and was led ... a panel of 28 genetic markers improved detection ... disease (CHD) (10-year risk ≥20%) over traditional risk ... important preventive strategy for CHD, because the current ... "The results indicate that genetic markers could be ...
(Date:5/20/2013)... May 20, 2013 BenefitMall, ... employee benefit, payroll products and services and CompuPay, ... are selected as finalists for the 2013 American Business ... of the Year category, and CompuPay is a finalist ... will ultimately be a Gold, Silver or Bronze Stevie® ...
(Date:5/20/2013)... 20, 2013 With the economic recession taking ... of coupons has seen a significant rise. Jessica Hacker proclaims ... coupons one way or the other. However, some people are ... as an ineffective measure to save money. Therefore, in order ... masses about its use, the online classes offered by Jessica ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Dr. Fanny J ... Brilliant, a gentle fractional laser treatment clinically proven to fight ... Clear + Brilliant are designed to prevent and ... + Brilliant can visibly illuminate skin tone, renew and smoothen ... skin, and reduce the appearance of pores. Developed by the ...
(Date:5/20/2013)... SUNDAY, May 19 (HealthDay News) -- Sleep apnea, the ... and subconsciously waking them up, becomes more common as ... possibility that it may somehow cause -- or be ... just yet if you have sleep apnea. The research ... no connection between the two conditions. Still, scientists found ...
Breaking Medicine News(10 mins):Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 2Health News:BenefitMall And CompuPay, Inc., A BenefitMall Company, Named As Finalists In 2013 American Business Awards 3Health News:Online Couponing Classes Offered by Jessica Hacker to Save Hundreds of Dollars 2Health News:Delaware Dermatologist Now Offers Clear + Brilliant Gentle Laser Skin Rejuvenation Treatments 2Health News:Sleep Apnea in Seniors Tied to Alzheimer's in Study 2Health News:Sleep Apnea in Seniors Tied to Alzheimer's in Study 3
... The following was,released today by the Democratic National ... cash in Saint Louis today,56,900 uninsured children in Missouri ... will finally say whether he supports,President Bush,s threat to ... week, President Bush is expected to veto a Democratic ...
... that typically fight bacteria, study finds , MONDAY, Oct. ... urban air pollution, shuts down early immune responses in ... vulnerable to bacteria and other foreign invaders, research shows. ... with increased cardiovascular and pulmonary hospitalizations and deaths, but ...
... Team that Provided Critical Services ... to Over 1,000 in 5 ... half of the husband and wife team that makes up La ... usually focus their attention on the dental needs of their North,County ...
... 1 Consumers are more concerned than ever,about the products ... is now more than just an every day routine, it ... Pure & Natural introduces a,new line of personal care products, ... new product line delivers more than just personal,care benefits; it ...
... Mich., Oct. 1 In an effort to,communicate ... it relates to,adult and embryonic stem cell research, ... bishops have launched a monumental,internal statewide education program ... parishes., The Church,s support for adult stem ...
... Cheryl Servais, MPH, RHIA, VP of Compliance and ... for a legal health record, WAYNE, Pa., ... peak performance within Health Information Management (HIM),departments, today ... Officer, Cheryl Servais, MPH, RHIA, authored The Legal ...
Cached Medicine News:Health News:Missouri Children to Mitt Romney: Show Me Your Health Care Priorities 2Health News:San Diego Dentist Haunted by Smiles in Dominican Republic 2Health News:Pure & Natural: Introducing an Effective, Healthy Approach to Personal Care and Beyond 2Health News:Pure & Natural: Introducing an Effective, Healthy Approach to Personal Care and Beyond 3Health News:Michigan Catholic Conference Launches Massive Internal Stem Cell Education Program 2Health News:Michigan Catholic Conference Launches Massive Internal Stem Cell Education Program 3Health News:Precyse Executive Authors New Book, The Legal Health Record 2
... acclaimed GT-CAPTURE digital camera photomicrographic system can ... such as Olympus, Leica, Nikon, and Zeiss, ... transferring images over the Internet easy and ... a performance-proven Nikkor lens. The system records ...
... digital camera photomicrographic system can be mounted ... Olympus, Leica, Nikon, and Zeiss, making building ... over the Internet easy and fast. Featuring ... Nikkor lens. The system records photomicrographic images ...
... Brilliant digital images with advanced ... Stepping) high density imaging technology offers ... up to 12 million output pixels ... enabling enlarged image data for documentation ...
... from Carl Zeiss developed ... microscopy expert. Not only does ... in all image formats, it ... work with the microscope and ...
Medicine Products: